Sven Dethlefs, Celea Therapeutics CEO
PureTech spins out its IPF drug as it readies for Phase 3 meeting with the FDA
PureTech Health is shipping its lead drug to a new company called Celea Therapeutics in a move that follows the biotech’s playbook of setting up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
